X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT GLENMARK PHARMA/
WOCKHARDT
 
P/E (TTM) x 19.0 -14.3 - View Chart
P/BV x 3.4 1.7 198.4% View Chart
Dividend Yield % 0.3 0.0 13,730.5%  

Financials

 GLENMARK PHARMA   WOCKHARDT
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
WOCKHARDT
Mar-18
GLENMARK PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs9301,012 91.9%   
Low Rs517532 97.3%   
Sales per share (Unadj.) Rs322.6355.9 90.7%  
Earnings per share (Unadj.) Rs28.5-60.3 -47.3%  
Cash flow per share (Unadj.) Rs39.2-46.8 -83.8%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.30 21,327.9%  
Book value per share (Unadj.) Rs183.0257.8 71.0%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.2 103.4%   
Avg P/E ratio x25.4-12.8 -198.4%  
P/CF ratio (eoy) x18.5-16.5 -111.9%  
Price / Book Value ratio x4.03.0 132.1%  
Dividend payout %7.00 -42,316.6%   
Avg Mkt Cap Rs m204,20685,379 239.2%   
No. of employees `00013.76.3 219.3%   
Total wages/salary Rs m18,7189,371 199.8%   
Avg. sales/employee Rs Th6,636.86,295.0 105.4%   
Avg. wages/employee Rs Th1,364.71,498.3 91.1%   
Avg. net profit/employee Rs Th586.1-1,066.3 -55.0%   
INCOME DATA
Net Sales Rs m91,03139,369 231.2%  
Other income Rs m9141,202 76.0%   
Total revenues Rs m91,94540,571 226.6%   
Gross profit Rs m16,15418 88,272.1%  
Depreciation Rs m3,0191,495 201.9%   
Interest Rs m2,8562,555 111.8%   
Profit before tax Rs m11,193-2,830 -395.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m3,155257 1,227.5%   
Profit after tax Rs m8,039-6,669 -120.5%  
Gross profit margin %17.70 38,176.0%  
Effective tax rate %28.2-9.1 -310.3%   
Net profit margin %8.8-16.9 -52.1%  
BALANCE SHEET DATA
Current assets Rs m69,88733,796 206.8%   
Current liabilities Rs m32,87926,917 122.1%   
Net working cap to sales %40.717.5 232.7%  
Current ratio x2.11.3 169.3%  
Inventory Days Days8179 102.6%  
Debtors Days Days9389 104.8%  
Net fixed assets Rs m28,89239,664 72.8%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m51,35327,968 183.6%   
Net worth Rs m51,63528,522 181.0%   
Long term debt Rs m41,41821,731 190.6%   
Total assets Rs m125,95481,620 154.3%  
Interest coverage x4.9-0.1 -4,575.6%   
Debt to equity ratio x0.80.8 105.3%  
Sales to assets ratio x0.70.5 149.8%   
Return on assets %8.6-5.0 -171.6%  
Return on equity %15.6-23.4 -66.6%  
Return on capital %15.1-7.7 -196.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3179,807 370.3%   
Fx outflow Rs m9,7201,789 543.4%   
Net fx Rs m26,5988,019 331.7%   
CASH FLOW
From Operations Rs m16,481684 2,408.0%  
From Investments Rs m-10,1336,302 -160.8%  
From Financial Activity Rs m-4,685-7,695 60.9%  
Net Cashflow Rs m1,770-664 -266.6%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS